Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live
18 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
18
Total Reports
6
Deaths Reported
3330.0%
Death Rate
Active Ingredients
Canine Adenovirus Type 2,Toronto A/26/61,LiveCanine Coronavirus,K-378/51,LiveCanine Distemper,Vcp258,VectorCanine Parainfluenza Virus,D-008,LiveCanine Parvovirus,780916,Live
Administration Routes
SubcutaneousUnknown
Species Affected
Dog 18
Most Affected Breeds
Retriever - Labrador 6
Crossbred Canine/dog 1
Boxer (German Boxer) 1
Rottweiler 1
Dog (unknown) 1
Poodle - Toy 1
Bulldog - French 1
Collie - Border 1
Doberman Pinscher 1
Chihuahua 1
Most Reported Reactions
Vomiting 7
Lack of efficacy (virus) - parvovirus (including feline panleukopenia) 6
Death 5
Lethargy (see also Central nervous system depression in 'Neurological') 3
Anaemia NOS 3
Not eating 3
Proprioception deficit 2
Leucocytosis NOS 2
Neutrophilia 2
Fever 2
Elevated serum alkaline phosphatase (ALP) 2
Low blood urea nitrogen (BUN) 2
Outcome Breakdown
Recovered/Normal
7 (36.8%)
Died
5 (26.3%)
Outcome Unknown
4 (21.1%)
Ongoing
2 (10.5%)
Euthanized
1 (5.3%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.